Neil Woodford Buys Horizon Discovery Group PLC And More GlaxoSmithKline plc & AstraZeneca plc

Catching my eye among Neil Woodford’s latest buys are Horizon Discovery Group PLC (LON:HZD), GlaxoSmithKline plc (LON:GSK) and AstraZeneca plc (LON:AZN).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Ace fund manager Neil Woodford engaged in a good deal of trading during May. His flagship CF Woodford Equity Income Fund was active in the blue-chip arena, but also bought into a number of new small caps. The latter are the type of companies that will figure more prominently in his recently-launched growth fund, Patient Capital Trust.

New small-cap buy Horizon Discovery (LSE: HZD) caught my eye, while Woodford’s team also had some interesting comments to make on the big pharma sector, as the fund dumped its holding in French group Sanofi and bought more shares in GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) and AstraZeneca (LSE: AZN) (NYSE: AZN.US).

Blue chips

Drugs giants have long been core holdings in Woodford’s portfolios, as the master investor sees “a fundamentally undervalued industry”.

As the purchase of more GlaxoSmithKline and AstraZeneca testifies, Woodford’s sale of Sanofi doesn’t signal a change of heart on the sector. Sanofi is “simply a casualty of the competition for capital in the portfolio”. A good run up in the French firm’s shares provided an “opportunity to sell and reinvest in companies that we view as even more attractive in terms of long-term total return potential”.

Longstanding holding GlaxoSmithKline has been “frustratingly disappointing” for much of the time Woodford has held it.

“It is valued by the market as a struggling pharmaceuticals business — a view that we have some sympathy with because the pharma business [two-thirds of turnover] has performed poorly operationally”.

However, Woodford’s team reckons the market has got it wrong by failing to appreciate the other areas of Glaxo’s business: vaccines and consumer healthcare:

“In particular, the current share price dramatically underappreciates the value of ViiV healthcare, Glaxo’s specialist HIV business. We continue to see considerable inherent value in Glaxo, however, and believe the sum of the parts to be significantly greater than the whole”.

Glaxo’s shares were trading above £14 throughout May, when Woodford was buying, but you can currently pick them up below that level on a forward P/E of 17 with a dividend yield of 5.8%.

AstraZeneca’s shares are also cheaper now than during May. They’re currently trading at around £42.50 on a forward P/E of 15.5 with a 4.4% yield.

Woodford was disappointed with news during May that US group Amgen had terminated its partnership with Astra to develop psoriasis treatment brodalumab. However, Woodford’s team remain bullish on the UK company, maintaining that Amgen’s withdrawal “doesn’t undermine an investment case which is supported by an excitingly diverse pipeline of potential new therapies”.

Elsewhere, among the blue chips, Woodford was happy to continue adding to Centrica and Legal & General, as well as to mid caps Homeserve and IP Group.

Small caps

Woodford introduced a number of small caps to the fund during May. Some of these are unquoted companies or listed overseas (for example, Norwegian fingerprint technology business Idex), but some are more readily accessible to the average UK private investor.

The fund took “a small but extremely interesting position” in Verseon, a US-based but UK-listed firm that applies a physics-based approach to drug discovery, and also bought into AIM-listed Horizon Discovery, a life sciences business which supplies research tools and services to help translate the human genome and accelerate the discovery of personalised medicines.

Horizon Discovery did a placing at 190p a share to raise £25m at the beginning of May. Woodford’s participation in the placing gave him a stake in the company of over 11%. Horizon is currently loss-making (£5.9m last year), but the proceeds of the placing will enable the company to accelerate growth, and you can currently pick up the shares below the placing price; they trade at 180p, as I write.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline and Homeserve. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »